US20170166624A1
University of Texas System
Certain embodiments are directed to TGF-β inhibitors EUc and REUc. EUc is generated by removing the non-binding N-terminal subdomain from the TGF-β type III receptor, and REUc is generated by fusing together the binding domains of the TGF-β type II (RII or R) and type III receptor (RIII or EU) by …